Studies related to Subjective Well-Being and Vinpocetine

[Efficacy Of Vinpotropile In The Therapy Of Initial Signs Of Cerebrovascular Pathology]

Effect Increase
Trial Design Cohort
Trial Length 1-6 months
Number of Subjects 20
Sex Both Genders
Age Range 45-64, 65+
Body Types Overweight
Notes for this study:
Used vinpotropile (Pyracetam) as oral dose for 30 days in patients aged 50-78 with beginning stages of chronic brain ischemia. The rate of cognitive decline appears to be attenuated as assessed by the MMSE rating scale, and subjective well being increased.

Full details on all 2 studies are available to Examine Members. Try out the Examine Membership with a 14-day free trial.

Already a Member? Log in now to access.